Search clinical trials for: CRAD001H

Total 14 results

Chang Gung Memorial Hospital

Completed

Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient

Liver Transplantation

Taiwan
Medical College of Wisconsin

Withdrawn

Myfortic in High MELD Liver Transplantation

High Model for End-Stage Liver Disease (MELD) Score

United States
Novartis Pharmaceuticals

Completed

A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. (REDUCE)

Liver Transplant

Spain
Novartis Pharmaceuticals

Completed

Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients (HEPHAISTOS)

Liver Transplantation

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

Liver Transplantation

United States, Japan, Saudi Arabia, Taiwan, Egypt, Italy, Korea, Republic of, Germany, India, Canada, Russian Federation, Singapore, Turkey
Novartis Pharmaceuticals

Completed

REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy (REFLECT)

Liver Transplantation

Italy
Novartis Pharmaceuticals

Completed

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

Liver Transplant Recipient

Belgium, Spain, Germany, Italy, Australia, United States, Netherlands, Ireland, Sweden, Brazil, Colombia, France, Russian Federation, Argentina, Czechia, United Kingdom
Novartis Pharmaceuticals

Withdrawn

Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients. (Prometheus)

Liver Transplantation
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

Renal Function | Liver Transplant

United States, Germany, Spain, Belgium, France, Hungary, Australia, Sweden, Italy, Canada, United Kingdom, Denmark
Novartis Pharmaceuticals

Completed

A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients (SIMCER)

Liver Transplantation

France
Novartis Pharmaceuticals

Completed

Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy

Liver Transplantation

Germany, Netherlands, Switzerland, Austria
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients (RAD)

Liver Transplantation

United States, Belgium, Colombia, Spain, Germany, Italy, Australia, Israel, France, Hungary, Netherlands, Argentina, Canada, Ireland, Sweden, Brazil, United Kingdom, Russian Federation, Czech Republic
Novartis Pharmaceuticals

Terminated

Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection (REVERT)

Recurrent Hepatitis C

Argentina
Novartis Pharmaceuticals

Completed

RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency

Liver Transplantation

Switzerland, Germany

3

Subscribe